IntegriChain offers three channel integrity analytics packages:

Market Vigilance™, Brand Vigilance™ and Demand Vigilance™.

Market Vigilance™ monitors the channel for illicit trading activities including counterfeit and parallel importation.

Brand Vigilance™ quantifies product diversion, reduces chargebacks and rebates and identifies the geographic regions and businesses engaged in illicit trade.

Demand Vigilance™ validates outlet-level demand data, both retail and non-retail and identifies data integrity and completeness problems improving forecasting and product visibility across the channel. 

IntegriChain Vigilance™ analytics allow manufacturers to identify and monitor the impact of commercial decisions on all outlets and points of care in the channel with an emphasis on the integrity of the channel. 

IntegriChain integrates and enhances channel and demand data flows to provide nearly 100% coverage of the U.S. channel with significantly increased granularity and timeliness.

Extensive pharmaceutical-industry experience provides the foundation for the IntegriChain Platform: Dossier™ profiles, enrichment services and analytic engines that check millions of manufacturer transactions against our U.S. channel map.

Proprietary Data and Enrichment Services
IntegriChain leverages its authoritative Dossier™  profiles of more than 150,000 outlets and 350,000 points of care in the channel to overcome today's principal data integrity and integration barriers to channel transparency. In addition, IntegriChain monitors product listings and prices at hundreds of secondary wholesalers, internet pharmacies and "bulk" sites that sell illicit, diverted and counterfeit products.  Enriching channel and demand data sets with this proprietary data provides tremendous insight into those outlet behavior and the impact of commercial decisions on channel integrity. 

Dossier Bridges™ makes it possible to dynamically connect channel data and demand data through an integrated data model.  Dossier Bridges™ connect ex-factory sales, trade partner inventories (852) and sales (867), chargebacks (844) and third party measures of demand from IMS and Wolters Kluwer.  Dossier Bridges™ reconcile each channel data transaction to a common outlet or provider identifier, class of trade (including a manufacturer's unique class of trade), and parent/child relationship. In addition, newly emerging data sets involving RFID, ePedigree and prescriber behavior can be quickly and easily integrated into Dossier Bridges™.

Proprietary Analytics and Reports
IntegriChain continues to develop and enhanced a growing set of analytics and reports that utilize Dossier Bridges™ to both monitor for data integrity problems as well as provide more granular and timely visibility into channel activity.  Commercial activities that are monitored include:

• Diversion from price advantaged customers or across classes of trad.
• Stock-outs at pharmacies and hospitals.
• Parallel importation from price advantaged countries.
• Excess chargeback payments for returned or canceled orders.
• Overpayment of rebates in managed care environments.
• Retail inventory speculation.

Periodic reports and alerts reveal the extent of high-risk commercial activity in the channel enabling manufacturers to take effective actions. 

Domain Expertise
IntegriChain leverages deep pharmaceutical industry expertise in working with channel and demand data sets to build high performance analytic services for pharmaceutical manufacturers.

Company experts have analyzed the impact of commercial decisions on channel integrity for a growing number of pharmaceutical manufacturers and more than $40 billion in U.S. product. From this unique perspective, the company enriches data, builds analytics and produces data that yields valuable and useful information to help manufacturers ensure channel integrity.